Tin tức & Cập nhật
Lọc theo Chuyên ngành:

DISCREET highlights apremilast potential for genital psoriasis
Individuals with psoriasis creeping into their intimate areas may find relief from apremilast, as shown by the week-32 improvements in multiple disease parameters in the phase III DISCREET study.
DISCREET highlights apremilast potential for genital psoriasis
22 Oct 2024
Induction chemo followed by chemoradiotherapy bumps up survival in advanced cervical cancer
A short-course induction chemotherapy conducted prior to chemoradiotherapy appears to deliver significant survival boost in locally advanced cervical cancer, according to the phase III GCIG INTERLACE trial.
Induction chemo followed by chemoradiotherapy bumps up survival in advanced cervical cancer
21 Oct 2024
IV iron replacement safe, effective for anemia after variceal bleed in cirrhosis patients
Patients with cirrhosis with iron deficiency anemia after variceal bleed (VB) can rely on the efficacy and safety of intravenous (IV) iron replacement, reports a study.
IV iron replacement safe, effective for anemia after variceal bleed in cirrhosis patients
21 Oct 2024
TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment
The clinical response or survival benefit derived by patients with advanced cutaneous melanoma from adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) does not wane even with prior antiprogrammed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) treatment, according to a study. TIL therapy also provides benefits in the second-line setting after anti-PD-(L)1 treatment.
TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment
21 Oct 2024
Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients
In a real-world analysis evaluating four oral antiviral agents for the treatment of COVID-19, two ritonavir-based regimens fared better than molnupiravir and azvudine in reducing hospital stay among patients hospitalized for mild or moderate disease.
Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients
21 Oct 2024
Second-line tislelizumab + anlotinib + chemo shows potential to improve ES-SCLC survival
A treatment regimen combining tislelizumab, anlotinib, and two cycles of irinotecan in the second-line setting demonstrates favourable efficacy and safety in patients with extensive-stage small cell lung cancer (ES-SCLC), according to the results of the single-arm phase II ESTAIL study.